PLGA-based nanoparticles: an overview of biomedical applications.

By F. Danhier, E. Ansorena, Joana M. Silva, R. Coco, Aude Le Breton, V. Préat. Journal of Controlled Release, 2012

3,515 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nanoparticle vaccines. (2014, background): “PLG and PLGA nanoparticles have been the ost extensively investigated due to their excellent biocompatiility and biodegradability [35,36].”
Polymeric nanoparticles: Promising platform for drug delivery. (2017, background): “…assembly like polylactides (PLA) (Edlund and Albertsson, 2002; Musumeci et al., 2006; Zambaux et al., 1998), poly (lactide co-glycolides) (PLGA) (Danhier et al., 2012; Demento et al., 2009; Derakhshandeh et al., 2007; Grabrucker et al., 2011; Kalaria et al., 2009), polyglycolides (PGA)…”
Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy (2015, background): “As a result, exosomes accumulated in considerably greater levels in PC12 cells than PLGA nanoparticles that have been used as common nanocarriers for PD therapy [90] or liposomes [71, 91].”
Biocompatibility of engineered nanoparticles for drug delivery. (2013, background): “reviewed the beneficial usage of PLGA-based nanoparticles both in vitro and in vivo as a therapeutic strategy in different diseases [48]; they also”
Cancer nanomedicine: a review of recent success in drug delivery (2017, background): “This reduction in clearance not only increases the half-life of the nanoparticle but also improves its bioavailability [9, 10].”